文献速递药物不良反应与药物警戒

多发性硬化患者使用移动应用报告药物不良反应的整群随机对照试验

Adverse Drug Reaction Reporting Using a Mobile Device Application by Persons with Multiple Sclerosis: A Cluster Randomized Controlled Trial.
PubMed 文献 · Drug Saf · 2020-10-13

VigipSEP研究为开放多中心整群随机对照试验,比较移动应用My eReport France®与传统方式(邮件、电话、国家网站)对多发性硬化患者报告疑似药物不良反应的影响。应用组每患者平均报告数为0.47,对照组为0.03(p=0.002);个体水平分析显示应用组报告相对风险为18.6(95%CI 4.1-84.2;p<0.001)。结论为移动应用可增加患者报告。

要点

  • 移动应用组每患者平均ADR报告数0.47,显著高于对照组的0.03(p=0.002)。
  • 个体水平分析中应用组ADR报告相对风险为18.6(95%CI 4.1-84.2;p<0.001)。
  • 研究提示移动应用可提升多发性硬化患者对一线疾病修正药物的ADR报告。

核心结论

  • 使用移动应用可增加接受一线疾病修正药物的多发性硬化患者对疑似药物不良反应的报告。

主要发现

  • 应用组中心每患者平均ADR报告数为0.47,对照组为0.03(p=0.002)。
  • 个体水平分析中,应用组相比对照组的ADR报告相对风险为18.6(95%CI 4.1-84.2;p<0.001),校正性别和疾病修正药物类型。

临床怎么用

  • 可考虑向接受一线疾病修正药物的多发性硬化患者推广移动应用以促进ADR自我报告。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

INTRODUCTION: Patient reporting adds value to pharmacovigilance. Encouraging it to be done through a mobile device application (App) is a method that should be evaluated. OBJECTIVE: This study aimed to determine whether the use of an App, compared to traditional use through e-mail, telephone, or the national website, increased suspected adverse drug reaction (ADR) reporting by persons with multiple sclerosis receiving a first-line disease-modifying drug. METHODS: An open multi-centric, cluster-randomized controlled trial was conducted (VigipSEP study). Clusters were centers allocated (1:1) to the use of the My eReport France® App (experimental arm), and traditional reporting (control arm). Persons with multiple sclerosis initiating or switching to a first-line disease-modifying drug between April 2017 and April 2019 were included. The primary outcome was the mean number of ADR reports per patient for the center-level analysis, and the number of ADR reports per patient for the individual-level analysis using the hierarchical Poisson regression model. RESULTS: Twenty-four centers (12 per arm: six public neurologists from the multiple sclerosis academic expert centers, three public neurologists from general hospitals, and three private practice neurologists) were randomized, including 159 patients. The mean number of ADR reports per patient was significantly higher in centers that used the App: 0.47 vs 0.03 in control centers (p = 0.002). At an individual-level analysis, the experimental arm was significantly associated with a relative risk of ADR reports at 18.6 (95% confidence interval 4.1-84.2; p < 0.001), compared to the control arm, adjusted for sex and type of disease-modifying drug. CONCLUSIONS: The use of a mobile App increased the ADR reporting by persons with multiple sclerosis receiving a first-line disease-modifying drug. CLINICALTRIALS. GOV IDENTIFIER: NCT03029897, registered in 2017.

来源:Drug Saf,查看原文。版权归原作者所有。

引用

  1. Defer G, Fedrizzi S, Chevanne D, et al. Adverse Drug Reaction Reporting Using a Mobile Device Application by Persons with Multiple Sclerosis: A Cluster Randomized Controlled Trial. Drug Saf. 2020. PMID: 33048319. doi:10.1007/s40264-020-01009-z

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。